Skip to main content
OpenTrials
Completed

NCT Number: NCT00005675

Oral Type I Collagen for Relieving Scleroderma

Diffuse systemic sclerosis (SSc), or scleroderma, is a connective tissue disease causing damage to skin and other organs. The purpose of this study is to determine if taking oral bovine type I collagen (CI) will improve the condition of SSc patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Alabama at Birmingham, Birmingham, Alabama, United States

Loading trial locations.

About this study

SSc is a chronic connective tissue disease that is caused by excess collagen deposits that damage the skin and other organs. This study will determine if a daily oral dose of bovine CI will improve the condition of patients with SSc.

Patients will be randomly assigned to one of two groups. The first group will receive 500 mcg bovine CI daily for 15 months; the second group will receive placebo. Study visits will be conducted at Months 4, 8, 12, and 15. Patients will undergo physical examination and blood tests at each visit. Patients will also be evaluated for modified Rodnan skin score (MRSS) and will be given health assessment questionnaires. A chest x-ray will be conducted at study entry and pulmonary function tests will be conducted at study entry and Month 12.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of diffuse systemic scleroderma (by American College of Rheumatology criteria 1980) of 10 years or less
  • Stable skin involvement by history or physical examination 6 months prior to study entry
  • Stable modified Rodnan skin score (MRSS) for 1 month prior to study entry
  • Stable MRSS of 16 or more at screening and stable MRSS between screening and baseline visit
  • Agree to use acceptable forms of contraception

Exclusion criteria

  • Participation in another clinical research study involving evaluation of another investigational drug within 90 days prior to study entry
  • Concurrent serious medical condition which, in the opinion of the investigator, makes the patient inappropriate for the study
  • Systemic sclerosis-like illnesses associated with environmental, ingested, or injected agents, such as L-tryptophan, tainted rapeseed oil, vinyl chloride, or bleomycin
  • Limited and localized (morphea) or linear SSc
  • Tenderness or swelling of the extremities (eosinophilic fasciitis)
  • Pregnancy
  • Use of certain medications
  • Allergy to beef or dairy products
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) within 1 week before baseline visit. Aspirin at 325 mg or less daily for stroke or heart attack prevention is allowed.
  • Use of herbal and some alternative therapies
  • Any organ transplant or stem cell transplant

Treatment and study plan

Oral bovine type I collagen

Drug

500 mcg of CI daily for 15 months

Other names: CI

Placebo

Drug

CI placebo daily for 15 months

Primary outcomes

  1. Disease condition, as measured by physical exam, modified Rodnan skin score (MRSS), health assessment questionnaires, chest x-ray, and pulmonary function tests

    Time frame: Measured at Month 12

Sponsors and collaborators

Lead sponsor

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Nih

Collaborators

  • Baltimore VA Medical Center
  • Beth Israel Medical Center
  • Georgetown University
  • Johns Hopkins University
  • Medical University of South Carolina
  • Northwestern University
  • UTHSC
  • University of Alabama at Birmingham
  • University of California, Los Angeles
  • Wayne State University

Registry information

Official study title

Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma

Important dates

Study start
2000
Primary completion
2005
First posted
May 29, 2000
Registry last updated
May 25, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.